Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173379 · ClinicalTrials.gov registry record · NA
Absorb IV Randomized Controlled Trial
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 2,604
- Enrollment target
NCT02173379: Completed NA study, sponsored by Abbott Medical Devices.
NCT02173379 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 2,604 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173379, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,604 participants
- Enrollment target
Study Summary
ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States. ABSORB IV is a continuation of ABSORB III (NCT01751906) trial which are maintained under one protocol because both trial designs are related. The data from ABSORB III and ABSORB IV will be pooled to support the ABSORB IV primary endpoint. Both the trials will evaluate the safety and effectiveness of Absorb BVS. The ABSORB IV Randomized Controlled Trial (RCT) is designed to continue to evaluate the safety and effectiveness as well as the potential short and long-term benefits of Abbott Vascular Absorb™ Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System (once commercially available), as compared to the commercially approved, control stent XIENCE.
Primary Outcome
Target lesion failure (TLF) composite of Cardiac Death, Myocardial Infarction attributable to Target Vessel (TV-MI), or Ischemia-Driven Target Lesion Revascularization (ID-TLR))
Interventions
- DEVICE XIENCE
- DEVICE Absorb BVS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,604 participants |
| Start Date | 2014-07 |
| Est. Completion | 2022-04-06 |
| Phase | NA |
What the finished NCT02173379 record still lists
NCT02173379 is an interventional study that assigns participants to a tested intervention. Its 2,604 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% higher).
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT02173379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02173379 about?
NCT02173379 is a clinical study titled "Absorb IV Randomized Controlled Trial". ABSORB IV is a prospective, randomized (1:1, Absorb BVS to XIENCE), single-blind, multi-center study, registering approximately 2610 subjects from approximately 140 sites in the United States and outside the United States. ABSORB IV is a continuation of ABSORB III (NCT01751906) trial which are maint...
What is the current status of trial NCT02173379?
This trial is currently completed. It is a NA study. The enrollment target is 2,604 participants. The study started on 2014-07. Estimated completion is 2022-04-06.
What interventions are being tested in trial NCT02173379?
The interventions under investigation include: XIENCE (DEVICE), Absorb BVS (DEVICE).
Who is sponsoring clinical trial NCT02173379?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02173379's enrollment target sits among peer trials
2,604 44th of 2000 higher than 1,957 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia